ArticleDermatologic therapy2022

Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.

Giacomo Caldarola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.